- Report
- February 2021
- 360 Pages
United States
From €2311EUR$2,400USD£1,988GBP
- Report
- February 2019
- 105 Pages
Global
From €1242EUR$1,290USD£1,068GBP
- Report
- June 2019
- 15 Pages
Global
€9630EUR$10,000USD£8,282GBP
- Report
- June 2019
- 15 Pages
Japan
€9630EUR$10,000USD£8,282GBP
- Report
- June 2019
- 14 Pages
Global
€9630EUR$10,000USD£8,282GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €482EUR$500USD£414GBP
- Report
- January 2019
- 35 Pages
Global
From €963EUR$1,000USD£828GBP
- Report
- June 2019
- 16 Pages
Global
€9630EUR$10,000USD£8,282GBP
Viread (tenofovir disoproxil fumarate) is an antiretroviral drug used to treat HIV/AIDS. It is a nucleotide reverse transcriptase inhibitor (NRTI) that works by blocking the action of reverse transcriptase, an enzyme that HIV needs to replicate. Viread is used in combination with other antiretroviral drugs to treat HIV infection. It is also used to prevent HIV infection in people who are at high risk of becoming infected. Viread is available in tablet and powder form and is taken orally.
The Viread market is a competitive one, with several companies offering their own versions of the drug. Companies such as Gilead Sciences, Mylan, and Teva Pharmaceuticals are all major players in the market. Other companies such as Cipla, Aurobindo Pharma, and Lupin Pharmaceuticals also offer generic versions of the drug. All of these companies offer Viread in various forms, including tablets, capsules, and powders. Show Less Read more
